Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use.

Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Ther Adv Hematol. 2012 Dec; 3(6):375-89.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.